An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development  by Komura, Shingo et al.
Stem Cell Reports
ArticleAn EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of
Impaired Osteogenic Differentiation on Osteosarcoma Development
Shingo Komura,1,2 Katsunori Semi,1,3 Fumiaki Itakura,1 Hirofumi Shibata,1 Takatoshi Ohno,2 Akitsu Hotta,1,3
Knut Woltjen,1,4 Takuya Yamamoto,1,3,5 Haruhiko Akiyama,2 and Yasuhiro Yamada1,3,*
1Laboratory of Stem Cell Oncology, Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University,
53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
2Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
3Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto 606-8507, Japan
4Hakubi Center for Advanced Research, Kyoto University, Kyoto 606-8501, Japan
5AMED-CREST, AMED 1-7-1 Otemach, Chiyodaku, Tokyo 100-0004, Japan
*Correspondence: y-yamada@cira.kyoto-u.ac.jp
http://dx.doi.org/10.1016/j.stemcr.2016.02.009
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYEWS-FLI1, a multi-functional fusion oncogene, is exclusively detected in Ewing sarcomas. However, previous studies reported that rare
varieties of osteosarcomas also harbor EWS-ETS family fusion. Here, using the doxycycline-inducible EWS-FLI1 system, we established an
EWS-FLI1-dependent osteosarcomamodel frommurine bonemarrow stromal cells.We revealed that thewithdrawal of EWS-FLI1 expres-
sion enhances the osteogenic differentiation of sarcoma cells, leading to mature bone formation. Taking advantage of induced pluripo-
tent stem cell (iPSC) technology, we also show that sarcoma-derived iPSCs with cancer-related genetic abnormalities exhibited an
impaired differentiation program of osteogenic lineage irrespective of the EWS-FLI1 expression. Finally, we demonstrate that EWS-
FLI1 contributed to secondary sarcomadevelopment from the sarcoma iPSCs after osteogenic differentiation. These findings demonstrate
thatmodulating cellular differentiation is a fundamental principle of EWS-FLI1-induced osteosarcoma development. This in vitro cancer
model using sarcoma iPSCs should provide a unique platform for dissecting relationships between the cancer genome and cellular
differentiation.INTRODUCTION
Cancer cells often exhibit similar properties to somatic
stem/progenitor cells of the tissue of origin (Reya et al.,
2001; Rossi and Weissman, 2006). Considering that pro-
genitor cells at the developmental stage and somatic
stem/progenitor cells in some adult tissues have the ability
for self-renewal and/or active proliferation, it has been pro-
posed that maintenance of the stem/progenitor cell state
could be a driving force for tumor development (Reya
et al., 2001). Osteosarcoma is a representative cancer that
exhibits shared features with normal stem/progenitor cells
(Luo et al., 2008; Thomas et al., 2004). The late markers of
osteogenic differentiation are silenced while the early
markers are modestly expressed in osteosarcomas (Luo
et al., 2008; Thomas et al., 2004). Moreover, more aggres-
sive phenotypes of osteosarcomas are correlated with fea-
tures of early osteogenic progenitors (He et al., 2010; Luo
et al., 2008), suggesting that defects in the osteogenic dif-
ferentiation program may play a role in osteosarcoma
development and progression. However, the causative ab-
errations that confer stem/progenitor cell properties on
osteosarcoma cells are not fully understood.
EWS-FLI1, a widely recognized fusion oncogene for
Ewing sarcomas, is generated by the chromosomal translo-
cation of t(11;22) (q24;q12), which consists of the N-termi-592 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authonal transactivator domain of the EWS gene and the C-ter-
minal ETS DNA binding domain of the FLI1 gene. The
resulting EWS-FLI1 fusion protein harbors multiple func-
tions, acting as a transcriptional activator, transcriptional
repressor, chromatin modulator, and splicing modulator
(Kinsey et al., 2006; Riggi et al., 2014; Selvanathan et al.,
2015; Smith et al., 2006). Despite the variety of oncogenic
functions of EWS-FLI1, a number of previous studies
implied that EWS-FLI1 expression itself is not sufficient
to induce Ewing sarcoma (Lin et al., 2008; Miyagawa
et al., 2008; Riggi et al., 2008; Tanaka et al., 2015) and
that other aberrations may be necessary. Indeed, genetic
variants near EGR2 and TARDBP are associated with
susceptibility to Ewing sarcoma (Grunewald et al., 2015;
Postel-Vinay et al., 2012). Moreover, additional genetic
mutations, such as TP53, CDKN2A, and STAG2, have
been identified in a subset of Ewing sarcomas (Crompton
et al., 2014; Tirode et al., 2014). However, it remains un-
clear whether these mutations are additional driver muta-
tions or passenger mutations and how they contribute to
the sarcoma development.
The derivation of induced pluripotent stem cells (iPSCs)
demonstrated thatmammalian somatic cells can be reprog-
rammed into pluripotent stem cells (Takahashi and Yama-
naka, 2006). It is noteworthy that the reprogramming
process does not require any particular alterations to thers
genetic information, which makes iPSC technology suit-
able to study the genotype-phenotype relationship in
various diseases (Soldner et al., 2009; Yamashita et al.,
2014). Considering that cancer is a genetic disease
involving genetic mutations, single nucleotide variants,
and structural abnormalities of the chromosome, iPSCs
derived from cancer cells are expected to harbor shared ge-
netic abnormalities with the parental cancer cells and
therefore should be a powerful tool for dissecting the role
of the cancer genome on the phenotype (Semi and Ya-
mada, 2015).
Here, we established a murine EWS-FLI1-induced osteo-
sarcomamodel from adult bonemarrow stromal cells using
a doxycycline (Dox)-inducible-EWS-FLI1 expression sys-
tem. We revealed that EWS-FLI1 expression inhibits the
osteogenic differentiation of sarcoma cells in vitro and
in vivo. Moreover, we found that iPSCs derived from the
EWS-FLI1-induced osteosarcoma cells exhibit impaired
osteogenic differentiation and give rise to sarcoma cells af-
ter osteogenic differentiation in vitro in conjunction with
EWS-FLI1 expression.RESULTS
Establishment of EWS-FLI1-Inducible ESCs and Mice
First, we tried to establish an EWS-FLI1-inducible mouse
model with locus targeting methods. We established two
transgenic systems using embryonic stem cell (ESC) lines
containing Dox-inducible EWS-FLI1 alleles that were inte-
grated at different loci by utilizing the KH2 system and
Rosa26 targeting vector (Figures 1A, S1A, and S1B) (Ohnishi
et al., 2014; Yamada et al., 2013; Beard et al., 2006). In both
ESC lines, reverse tetracycline-controlled transactivator
(rtTA) is expressed from the Rosa26 locus, and the Tet
operator-EWS-FLI1-ires-mCherry construct is integrated
into either the 30UTR of the Col1a1 locus (Rosa-M2rtTA/
Col1a1::tetO-EWS-FLI1) or Rosa26 locus (Rosa-M2rtTA/
Rosa::tetO-EWS-FLI1). Both ESCs expressed mCherry fluo-
rescence upon treatment with Dox in vitro (Figure 1B).
The inducible EWS-FLI1 expression in ESCs was also
confirmed by qRT-PCR and western blotting (Figure 1C).
Next, we performed blastocyst injection of EWS-FLI1-
inducible ESCs and obtained chimeric mice (Figure 1D
and Table S1). Upon Dox treatment, EWS-FLI1 was ex-
pressed in a wide variety of organs and tissues of the
mice, including the bone marrow and the cortex of the
bone where Ewing sarcomas often arise (Figures 1E, 1F,
and S1C). Some mice (Rosa-M2rtTA/Col1a1::tetO-EWS-
FLI1) died soon after EWS-FLI1 induction, which was
accompanied by dysplastic changes of intestinal cells
due to impaired differentiation (8 of 14 mice, Figures 1G
and S1D). However, despite the long-term induction ofStemEWS-FLI1 (up to 13 months), we did not observe any
EWS-FLI1-dependent tumor formation in either system
(Figure 1G).
Establishment of EWS-FLI1-Dependent Immortalized
Cells with the Dox-Inducible EWS-FLI1 Lentiviral
System
Our results suggested that the induction of EWS-FLI1 in
adult mice is not sufficient for sarcoma development.
Indeed, there is no report that shows the generation of
EWS-FLI1-driven sarcomas by the targeted insertion of
EWS-FLI1 except for one study that reported the develop-
ment of myeloid/erythroid leukemia (Torchia et al.,
2007). However, previous studies have succeeded in
modeling Ewing-like sarcomas in mice when combined
with Trp53 deletion or an integrating viral delivery system
with the EWS-FLI1 fusion gene, which is consistent with
the hypothesis that additional genetic mutations may be
required for EWS-FLI1-induced sarcomadevelopment (Cas-
tillero-Trejo et al., 2005; Lin et al., 2008; Riggi et al., 2005;
Tanaka et al., 2014).
Accordingly, we generated a lentiviral EWS-FLI1 expres-
sion vector with the Dox-inducible expression system (Fig-
ure 2A). A TetO-EWS-FLI1-ires-Neo cassette was lentivirally
transduced into bone marrow stromal cells from adult
Rosa26-M2rtTA/M2rtTAmice (3–4 weeks of age). The trans-
duced bone marrow cells were cultured with Dox and
G418. The surviving cells were subsequently cultured for
2 months in culture medium containing Dox and G418.
Although most cells with EWS-FLI1-inducible alleles did
not survive, we nevertheless obtained three immortalized
cell lines (EFN#2, EFN#12, and EFV#4; Figure 2B). The three
lines expressed EWS-FLI1mRNA and protein in response to
Dox (Figures 2C and 2D) and continuously proliferated
under the Dox-containing culture condition (Figure 2B).
Upon the withdrawal of Dox, the morphology of two cell
lines (EFN#2 and EFN#12) gradually changed to a flat shape
and proliferation was inhibited, whereas the third cell line
(EFV#4) did not show any evidence of Dox dependency in
terms of cellular kinetics (Figure S2A). These observations
show that we obtained two EWS-FLI1-dependent immor-
talized cell lines from murine adult bone marrow stromal
cells in vitro.
EWS-FLI1-Dependent Immortalized Cells Formed
Osteosarcomas In Vivo
To confirm whether the EWS-FLI1-dependent immortal-
ized cell lines have tumorigenic potential in vivo, we trans-
planted EFN#2 and EFN#12 into the subcutaneous layer of
immunocompromised mice. At 10 weeks after the inocula-
tion, the transplanted mice developed tumors from both
cell lines when they were given Dox (16/16 for EFN#2,
2/4 for EFN#12; Figures 2E and 2F), whereas no tumorCell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authors 593
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Figure 1. ESCs and Chimeric Mice with the Dox-Inducible EWS-FLI1 Expression System
(A) Schematic illustrations of the Dox-inducible EWS-FLI1 expression system. Two distinct ESC lines with Dox-inducible EWS-FLI1
expression alleles targeted at different loci were established. Upward triangles (white), rtTA; downward triangles (green), Dox.
(B) EWS-FLI1-inducible ESCs (Rosa-M2rtTA/Col1a1::tetO-EWS-FLI1-ires-mCherry). The mCherry signal was detectable upon Dox exposure for
24 hr. Top, bright field; bottom, mCherry. Scale bars, 200 mm.
(C) EWS-FLI1 mRNA and protein are detectable in ESCs upon Dox exposure for 24 hr. Data are presented as means ± SD (three technical
replicates). The expression level of Dox OFF cells was set to 1. Similar results were obtained in both ESC lines.
(D) Chimeric mice were generated by injecting EWS-FLI1-inducible ESCs into blastocyst.
(E) Immunohistochemistry of various organs of chimeric mice treated with Dox for 2–7 days. Anti-HA antibody was used to detect EWS-FLI1
fusion protein. EWS-FLI1-positive cells are observed in the bone cortex and the bone marrow after treatment with Dox. Scale bars, 100 mm.
(F) EWS-FLI1-positive cells were observed in various organs after treatment with Dox. Scale bars, 100 mm.
(G) EWS-FLI1 expression failed to generate sarcomas in chimeric mice derived from two ESCs. Some Rosa-M2rtTA/Col1a1::tetO-EWS-FLI1
mice died in the early phase, presumably because of a gastrointestinal disorder (Figure S1D). Some mice died in the late phase because of
EWS-FLI1-independent spontaneous cancer development such as lymphoma and lung cancer. Rosa-M2rtTA/Col1a1::tetO-EWS-FLI1 mice,
n = 14; Rosa-M2rtTA/Rosa::tetO-EWS-FLI1 mice, n = 9.formation was observed in mice without Dox administra-
tion (0/16 for EFN#2, 0/4 for EFN#12; Figures 2E and 2F).
Histological analysis revealed that the tumors consisted
of small round blue cells that resembled Ewing sarcomas.
However, tumor cells often showed osteoid formation (Fig-
ures 2G and S2B) and thus were considered small-cell oste-
osarcoma, which is a rare subtype of osteosarcomas. In
addition, immunohistochemistry showed that the tumor594 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authocells expressed EWS-FLI1 and were frequently positive for
Ki67, a marker for proliferating cells (Figure S2B).
Establishment of EWS-FLI1-Dependent Osteosarcoma
Cell Lines
To further investigate the properties of the EWS-FLI1-
induced osteosarcomas in detail, we established EWS-FLI1-
dependent osteosarcoma cell lines from subcutaneousrs
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Figure 2. EWS-FLI1-Dependent Small-Cell Osteosarcoma Model by Utilizing the Lentiviral EWS-FLI1 Expression System
(A) Schematic illustrations of the lentiviral EWS-FLI1 expression system. Lentivirus was introduced into bone marrow stromal cells
collected from Rosa26-M2rtTA mice. EWS-FLI1-expressing neomycin-resistant cells survived this protocol.
(legend continued on next page)
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osteosarcomas in immunocompromised mice inoculated
with EFN#2 and EFN#12 cells (SCOS#2 and SCOS#12,
respectively). As observed in the primary EWS-FLI1-depen-
dent immortalized cells, the established osteosarcoma cell
lines expressedEWS-FLI1 in aDox concentration-dependent
manner (FigureS2C)andactivelyproliferated inthepresence
of Dox (Figures 2H and S2D–S2F). After Dox withdrawal,
SCOS#2 and SCOS#12 changed their morphology and
stopped proliferating (Figure S2D). At the same time, we
found increased expressions of p53 and p21, but no increase
inb-gal (SAbgal) activity,which is associatedwith senescence
(Figure S2G). Upon re-administration of Dox, the growth-
arrested cells reacquired proliferative potential (Figure S2H).
The reversiblephenotype suggested thatEWS-FLI1depletion
results in cell-cycle arrest of the osteosarcoma cells.
Given that the genomic integration of lentivirus might
play a role in osteosarcoma development, we also deter-
mined the virus integration site of SCOS#2. We identified
a single integration at the intergenic region 13 kb down-
stream of Cd14 (Figure S2I), a location unlikely to act as a
genetic driver for sarcoma development.
To evaluate the similarity of the established EWS-FLI1-
dependent sarcoma cell lines with human Ewing sarcomas
and osteosarcomas, we compared global gene expression
profiles of the SCOSs by microarray analysis. We first
extracted genes that are specifically upregulated/downre-
gulated in human Ewing sarcomas compared with human
osteosarcomas and examined their expression in SCOS#2
and SCOS#12. We found that the gene expression patterns
of SCOSs exhibit partial similarities with both human
Ewing sarcomas and osteosarcomas (Figure S3A), suggest-
ing that SCOSs have shared characteristics with both Ewing
sarcomas and osteosarcomas.
Depletion of EWS-FLI1 Expression Promoted
Osteogenic Differentiation of Osteosarcoma Cells
To investigate the target of EWS-FLI1, we next compared
gene expression profiles between EWS-FLI1-expressing(B) The immortalized cells (EFN#2) grew rapidly in Dox-containin
morphological change in EWS-FLI1-expressing cells (4 days after the
(C) qRT-PCR results show EWS-FLI1 mRNA expression in Dox-treated s
replicates). The expression level of Dox OFF cells was set to 1.
(D) Western blotting using anti-HA antibody detected EWS-FLI1 prot
(E) EWS-FLI1-dependent immortalized cells (EFN#2) developed tumors
after the transplantation).
(F) Tumor weight at 10 weeks after the transplantation of EFN#2 with/
administration (n = 12, independent samples for each group). Error b
(G) Histology of EWS-FLI1-induced tumors in immunocompromised mi
round cells with various amounts of osteoid formation. The osteoid-ri
shown. Scale bars, 50 mm.
(H) Cell growth assay of the established EWS-FLI1-dependent sarcom
depended on EWS-FLI1 expression. Sarcoma cells without Dox exposu
means ± SD are shown in each group (two technical replicates per n;
596 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authoand non-expressing sarcoma cells using SCOS#2 and
SCOS#12. Intriguingly, in both cell lines, extracellular
matrix and space-related genes, which often include bone
and cartilage development-related genes, were significantly
enriched in Dox OFF sarcoma cells (for 72 hr) compared
with Dox ON EWS-FLI1-expressing sarcoma cells by GO
enrichment analysis (Figures 3A, 3B, and S3B). Previous
studies proposed that Ewing sarcoma could arise from
mesenchymal stem cells (MSCs) (Riggi et al., 2008, 2014;
Tirode et al., 2007). Long-term knockdown of EWS-FLI1
with shRNA in Ewing sarcoma cells resulted in cellular dif-
ferentiation to osteogenic, adipogenic, and chondrogenic
lineage, consistent with an MSC origin of Ewing sarcoma
(Tirode et al., 2007). Similarly, in the present study,
the short-term depletion of EWS-FLI1 in SCOS#2 and
SCOS#12 resulted in the promotion of osteogenic differen-
tiation with increased alkaline phosphatase activity (Fig-
ure 3C). Notably, after long-term depletion of EWS-FLI1,
a subset of sarcoma cells slowly proliferated and exhibited
heterogeneous morphology (Figure 3D). The EWS-FLI1-
withdrawn sarcoma cells expressed higher levels of
osteogenic differentiation marker genes, as well as chon-
drogenic and adipogenic genes (Figures 3E and S3C). More-
over, long-term culture without EWS-FLI1 expression led to
lipid production in a small subset of cells, as assessed by oil
red O staining (Figure S3D).
SCOS#2 andSCOS#12 formed small-cell osteosarcomas in
immunocompromisedmice givenDox. These sarcoma cells
had high proliferative activity based on Ki67 immunohisto-
chemistry (Figure 3F). Consistent with in vitro findings that
the growth of both SCOS#2 and SCOS#12 depends on
EWS-FLI1 expression, the subcutaneous tumors stopped or
retarded their growth after the withdrawal of Dox in vivo
(Figures 3F and 3G). Of particular note, histological analysis
revealed that the Dox-withdrawn tumors consisted of
osteoid and mature bone tissue with a small number of
blue cells (Figure 3F). These results indicated that deple-
tion of EWS-FLI1 promoted osteogenic differentiation ofg medium. Dox withdrawal resulted in growth retardation and
withdrawal). Scale bars, 200 mm.
amples (24 hr). Data are presented as means ± SD (three technical
ein in the presence of Dox (48 hr).
in immunocompromised mice only in the presence of Dox (10 weeks
without Dox administration. Tumor development depended on Dox
ars represent SD.
ce. Tumors are small-cell osteosarcomas, which consist of small blue
ch region (upper) and small blue round cell-rich region (lower) are
a cell lines (SCOS#2 and SCOS#12). The growth of sarcoma cells
re started to lose their growth at 3 days after Dox withdrawal. The
n = 3 biological replicates).
rs
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osteosarcoma cells in vivo. Together, our results highlight
the role ofEWS-FLI1 expressionon the suppressionof termi-
nal differentiation of osteosarcoma cells.
EWS-FLI1 Binds to the ETSMotif in EWS-FLI1-Induced
Osteosarcoma Cells
To investigate how EWS-FLI1 suppresses the expression
of osteogenic differentiation-related genes, we performed
chromatin immunoprecipitation sequencing (ChIP-seq)
analysis for hemagglutinin (HA)-tagged EWS-FLI1 in
SCOS#2 cells using anti-HA antibody. The analysis
identified 2,562 sites for EWS-FLI1 binding in EWS-FLI1-
expressing SCOS#2. A motif analysis with HOMER (hyper-
geometric optimization of motif enrichment) revealed that
these binding sites often contain the ETS binding motif
(Figure 3H), suggesting that EWS-FLI1 binds to the genome
through the C-terminal ETS binding domain of FLI1.
Previous studies demonstrated that EWS-FLI1 binds DNA
preferentially at GGAA repeats to activate transcription.
Indeed, we confirmed that the GGAA repeat is the most
representative motif of EWS-FLI1 binding in SK-N-MC, a
human Ewing sarcoma cell line (Figure 3I) (Riggi et al.,
2014). Notably, the GGAA repeat was not enriched in
SCOS#2 according to de novo motif analysis for EWS-
FLI1 binding (Figure 3I).
One target of EWS-FLI1 in human Ewing sarcoma,Nr0b1,
has 15 GGAA repeats 50 kb upstream from its transcription
start site (TSS) in mouse. ChIP-seq data revealed that EWS-
FLI1 does not bind to these GGAA repeats in SCOS#2,
which is consistent with the fact that Nr0b1 expression is
not affected by EWS-FLI1 expression in SCOS#2 (data not
shown). We found similar GGAA repeats upstream and
downstream of Nkx2-2, Ccnd1, and Dkk2, which are also
known targets of EWS-FLI1 binding in human EwingFigure 3. Inhibition of Osteogenic Differentiation by EWS-FLI1 in
(A) Gene ontology enrichment analysis showed that the extracellula
withdrawal in SCOS#2 cells. The upregulated genes were selected by
enriched clusters are highlighted.
(B) Scatterplot analysis revealed that a number of osteogenesis and
withdrawal in SCOS#2 cells.
(C) At 5 days after Dox withdrawal, sarcoma cells exhibited alkaline ph
(D) At 38 days after Dox withdrawal, slow-growing heterogeneous ce
(E) At 38 days after Dox withdrawal, cells showed higher expression o
were measured by qRT-PCR. Data are presented as means ± SD (three te
Sost, Fgf23, and Mepe were undetectable in Dox ON samples by qRT-
instead.
(F) H&E and alizarin red staining demonstrated that Dox withdrawal lea
increase of mature bone formation. Ki67 immunohistochemistry shows
bars, 200 mm (upper) and 50 mm (lower).
(G) In vivo tumor formation assay using sarcoma cell line SCOS#2 (n =
and mice were sacrificed at 7 weeks.
(H) The ETS motif was enriched in EWS-FLI1 binding sites according
(I) De novo motif analysis identified the GGAA repeat as the most fre
598 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authosarcomas. However, there was no clear enrichment of
EWS-FLI1 binding in SCOS#2. Ultimately, we found that
only four of 2,562 EWS-FLI1 binding sites in SCOS#2 con-
tained more than ten GGAA repeats, highlighting the
difference in EWS-FLI1 binding between human Ewing
sarcomas and our EWS-FLI1-induced osteosarcoma cells.
To further assess whether EWS-FLI1 binding affects the
expression of adjacent genes, we first identified 126 genes
that possess EWS-FLI1 binding sites close to their TSS
(±5 kb) and compared the expression between Dox (EWS-
FLI1) ON and Dox OFF cells. No obvious difference in the
expression levels of these genes was detected (Figure S4A).
Similarly, EWS-FLI1 binding was not enriched near the
TSSs of the genes upregulated or downregulated by Dox
exposure (517 and 588 genes, respectively; cutoff point at
fold change >1.5; Figure S4B). In contrast, the genome-
wide analysis of EWS-FLI1 binding revealed that EWS-
FLI1 was preferentially recruited to the distal intergenic
region (72.5% of total binding sites) (Figures S4C and
S4D). Our results indicate that EWS-FLI1 binds to the
genome via the ETS motif, but EWS-FLI1 binding at the
proximal regulatory region does not have a substantial
impact on altered gene expressions in EWS-FLI1-induced
osteosarcoma cells.
Establishment of iPSCs from EWS-FLI1-Induced
Osteosarcoma Cells
The derivation of iPSCs does not require specific changes
in the genomic sequence, making this technology appli-
cable for the evaluation of genetic context effects on cell
types and differentiation statuses. Given that additional
genetic aberrations may be required for EWS-FLI1-induced
sarcoma development, the establishment of iPSCs from
EWS-FLI1-induced sarcoma cells should provide a uniqueSmall-Cell Osteosarcoma Cells
r region and matrix-related genes are upregulated 72 hr after Dox
cutoff point at hold change >1.5 and p <1.0 3 104. The top five
chondrogenesis-related genes were upregulated 72 hr after Dox
osphatase activity. Scale bars, 50 mm (upper) and 200 mm (lower).
lls were observed. Scale bars, 200 mm.
f osteogenic differentiation-related genes. mRNA expression levels
chnical replicates). The expression level of Dox ON cells was set to 1.
PCR, therefore, the expression level of Dox OFF cells was set to 1
ds to a significant reduction of the small blue cell population and an
the active proliferation of sarcoma cells in Dox ON condition. Scale
7, independent tumor). Dox treatment was withdrawn at 3 weeks,
to motif analysis with HOMER of SCOS#2.
quent motif in SK-N-MC. This repeat was not found in SCOS#2.
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tool to study the impact of genetic abnormalities beyond
EWS-FLI1 expression on sarcoma development. We there-
fore tried to establish iPSCs from SCOS#2 and SCOS#12.
After single-cell cloning of sarcoma cells, we introduced
OCT3/4, SOX2, KLF4, and c-MYC into the sarcoma cells
and obtained iPSC-like colonies under the absence of
EWS-FLI1 expression (efficiency of colony formation was
0.0009%; Figures 4A and S5A). These iPSC-like cells ex-
pressed pluripotency-related genes, such as Nanog and
Oct3/4, at comparative levels with ESCs (Figure 4B). Simi-
larly, the global gene expression patterns of iPSC-like cells
were similar to those in normal ESCs and control iPSCs
(Figure S5B).
The sarcoma-derived iPSC-like cells exhibited demethy-
lation of both Nanog promoter and Oct3/4 distal enhancer
(Figure 4C), implying that these cells underwent epigenetic
reorganization to acquire pluripotency. The silencing of
the four exogenous factors, which occurs in the late stage
of cellular reprogramming, was observed in some iPSC-
like clones (Figure S5C), suggesting that these cells were
fully reprogrammed. Then, we performed array compara-
tive genomic hybridization (array CGH) and found
that the single-cell-derived sarcoma cells had extensive
chromosomal abnormalities (Figure S5D). Notably, sar-
coma-derived iPSC-like cells harbored some identical chro-
mosomal aberrations (Figure S5D). Furthermore, exome
analysis revealed hundreds of identicalmissensemutations
between SCOS#2 and sarcoma-derived iPSC-like cells (Fig-
ure S5E and Table S2), affirming that these iPSC-like clones
were derived from the parental sarcoma cell. A subset of theFigure 4. Establishment of Sarcoma-Derived iPSCs and Differenti
(A) iPSCs-like cells were established from sarcoma cells by introducin
(B) qRT-PCR revealed that the expression levels of pluripotency-relate
of ESCs. Data are presented as means ± SD (three technical replicates
(C) Bisulfite sequencing analyses revealed that the Nanog promoter a
derived iPSC-like cells. White and black circles indicate non-methylat
(D) Sarcoma iPSCs gave rise to teratomas consisting of ectodermal,
immunocompromised mice. Scale bars, 50 mm.
(E) Schematic illustrations of in vitro osteogenic differentiation.
(F) qRT-PCR analysis of osteogenic differentiation-related genes. Wi
tetO-EWS-FLI1), and two independent fibroblast-derived iPSCs with Ro
osteogenic differentiation experiments. Sarcoma-derived iPSCs and c
tiation were examined for the expression of osteogenic differentiation
per n; n = 3 biological replicates). The mean expression level of ESCs
(G) Alizarin red staining revealed extracellular calcium deposits staine
differentiation). Scale bars, 20 mm.
(H) Histological analysis of an osteogenic region with osteoid producti
producing cells derived from sarcoma iPSCs have higher proliferat
bars, 50 mm.
(I) Ki67 positive ratio of osteogenic regions in teratomas derived fr
dependent osteogenic regions in two independent sarcoma iPSCs te
teratomas, and nine independent osteogenic regions in two indepen
statistical analysis. Sarcoma iPSCs vs control iPSCs, p < 0.05; sarcoma iP
600 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authomutated genes was alsomutated in human Ewing sarcomas
and osteosarcomas by the COSMIC database (http://
cancer.sanger.ac.uk/cosmic) (Table S3). These sarcoma-
derived iPSC-like cells lacked the ability to contribute to
adult chimeric mice by blastocyst injection (data not
shown), presumably because of the extensive genetic ab-
normalities observed in the CGH analysis and exome
analysis. However, sarcoma-derived iPSC-like cells formed
teratomas consisting of cells differentiating into three
different germ layers when they were inoculated into the
subcutaneous tissue of immunocompromised mice (Fig-
ure 4D), indicating that they have pluripotency. These re-
sults affirm that we succeeded in generating iPSCs from
EWS-FLI1-induced osteosarcoma cells.
Sarcoma iPSCs Exhibit Impaired Osteogenic
Differentiation Irrespective of EWS-FLI1 Expression
The enhanced osteogenic differentiation of sarcoma cells
upon the depletion of EWS-FLI1 raised the possibility that
EWS-FLI1-dependent osteosarcomas arise from osteogenic
cells. Accordingly,we tried to induceosteogenic cells, a puta-
tivecell oforiginof the sarcomas, frompluripotent stemcells
in vitro in the absence of EWS-FLI1 expression (Figure 4E)
(Kim et al., 2010). In control ESCs and control iPSCs estab-
lished from the fibroblasts of EWS-FLI1-inducible chimeric
mice (Rosa-M2rtTA/Rosa:tetO-EWS-FLI1), osteogenic differ-
entiation stimuli induced osteogenic differentiation-related
genes, such as Runx2, Sp7, Col1a1, Pth1r, andDmp1 (day 17)
(Figure 4F). Although the stimuli also induced the expres-
sion of Runx2, a key transcription factor for osteogenication of Sarcoma iPSCs into Osteogenic Cells
g reprogramming transcription factors. Scale bars, 200 mm.
d genes in sarcoma-derived iPSC-like cells were equivalent to those
). The expression level of ESCs was set to 1.
nd the Oct3/4 distal enhancer region are demethylated in sarcoma-
ed and methylated cytosine at CpG sites, respectively.
mesodermal, and endodermal tissue in the subcutaneous tissue of
ld-type ESCs (V6.5), EWS-FLI1-inducible ESCs (Rosa-M2rtTA/Rosa::
sa-M2rtTA/Rosa::tetO-EWS-FLI1 alleles were used as controls in the
ontrol ESCs/iPSCs on day 0 and day 17 during osteogenic differen-
-related genes. The mean ± SD is shown (three technical replicates
on day 17 was set to 1.
d in blight reddish orange (day 28 after the induction of osteogenic
on in teratomas. Ki67 immunohistochemistry revealed that osteoid-
ive activities than those derived from control ESCs/iPSCs. Scale
om sarcoma iPSCs or control ESCs/iPSCs. The mean ± SD of six in-
ratomas, five independent osteogenic regions in the control iPSC
dent ESC teratomas are shown. The ANOVA test was used for the
SCs vs control ESCs, p < 0.01; control ESCs vs control iPSCs, p > 0.05.
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Figure 5. EWS-FLI1 Induces Sarcomas from Induced Osteogenic Cells in Concert with Genetic Aberrations
(A) EWS-FLI1 expression does not promote the growth of undifferentiated pluripotent stem cells. The means ± SD are shown in each group
(two technical replicates per n; n = 3 biological replicates).
(B) Schematic illustration of in vitro osteogenic differentiation and EWS-FLI1 induction. The induced osteogenic cells (17 days after the
induction of osteogenic differentiation) were subsequently treated with/without Dox for 2 weeks.
(C) The sarcoma iPSC-derived osteogenic cells acquired robust proliferation with Dox treatment, whereas control ESCs/iPSCs (Rosa-M2rtTA/
Rosa::tetO-EWS-FLI1)-derived osteogenic cells did not. Scale bars, 200 mm.
(legend continued on next page)
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differentiation, in sarcoma-derived iPSCs, the induction of
osteogenic genes downstream of Runx2 was impaired even
in the absence of EWS-FLI1 expression (day 17) (Figure 4F).
Upon the prolonged induction of osteogenic differentiation
(day 28), a mineralized region, as assessed by alizarin red
staining, was detected in all samples (Figure 4G). However,
the mineralized area was larger in control ESCs/iPSCs than
in sarcoma-derived iPSCs (Figure 4G). We also employed
the in vivo differentiation method of sarcoma iPSCs to
generate teratomas in immunocompromised mice. Both
the sarcoma iPSCs and the control ESCs/iPSCs formed tera-
tomas,whichcontained anosteogenic region in the absence
of EWS-FLI1 expression (Figure 4H). The Ki67-positive ratio
of sarcoma iPSC-derived osteogenic cells was significantly
higher than that of control ESC/iPSC-derived osteogenic
cells (p < 0.05 and p < 0.01, respectively) (Figure 4I). Collec-
tively, sarcoma-derived iPSCs exhibit impaired osteogenic
differentiation irrespective of EWS-FLI1 expression, suggest-
ing that genetic and epigenetic alterations besides EWS-FLI1
fusion also inhibit osteogenic differentiation and maintain
the proliferating progenitor state.
EWS-FLI1 Expression Induced Rapid Sarcoma
Development from Sarcoma iPSC-Derived Osteogenic
Cells
Finally, we tried to analyze the cooperative action between
EWS-FLI1 expression and the impaired differentiation asso-
ciated with genetic aberrations on sarcoma development.
EWS-FLI1 expression in both sarcoma iPSCs and control
ESCs/iPSCs (Rosa-M2rtTA/Rosa::tetO-EWS-FLI1) has no pro-
moting effect on cell growth under undifferentiated culture
conditions (Figure 5A). Next, we induced osteogenic differ-
entiation of sarcoma iPSCs and control cells in vitro and
then EWS-FLI1 expression (Figure 5B). At day 17 of the
osteogenic differentiation protocol, osteogenic precursor
cells derived from sarcoma iPSCs and control cells were
treated with Dox (Figure 5B). Of note, only the sarcoma-
derived osteogenic cells showed robust proliferation
in vitro in response to Dox at day 31 (Figures 5C and 5D).
Xenograft of these cells resulted in tumor development
only inmice givenDox (Figure 5E). Histological analysis re-
vealed that these xenograft tumors were sarcomas that con-
sisted of small round blue cells (Figure 5F). The secondary
sarcoma harbored shared genetic mutations with SCOS
(Figure S5E and Table S2). Osteogenic cells derived from
control ESCs/iPSCs did not exhibit obvious EWS-FLI1-(D) EWS-FLI1 expression in the induced osteogenic cells was detect
means ± SD (three technical replicates). The mean expression level o
(E) Osteogenic cells induced with EWS-FLI1 developed tumors in immun
treatment).
(F) Histologically, developed tumors were sarcomas consisting of sm
immunohistochemistry revealed that sarcoma cells express EWS-FLI1.
602 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authodependent growth in vivo (data not shown), affirming
that sarcoma development requires additional aberrations.
Interestingly, these tumors often contained a carcinoma
component, therefore they were regarded as carcinosar-
comas (Figure S5F). Presumably, this component reflected
the contamination of heterogeneous cell types after
in vitro osteogenic differentiation of the sarcoma iPSCs.
Together, these results suggest that the impaired differenti-
ation potential associated with the sarcoma genome con-
tributes to a rapid malignant transformation of osteogenic
cells upon EWS-FLI1 expression.DISCUSSION
Although the exact cell of origin of Ewing sarcoma remains
to be determined, it is suggested that Ewing sarcomas may
arise from MSCs, which reside in the bone marrow (Riggi
et al., 2008; Tirode et al., 2007). In the present study, we
introduced the EWS-FLI1 fusion gene to bonemarrow stro-
mal cells to establish an Ewing sarcomamouse model (Cas-
tillero-Trejo et al., 2005; Riggi et al., 2005). We successfully
generated EWS-FLI1-induced sarcomas that depended on
EWS-FLI1 expression in terms of in vitro proliferation
and in vivo tumor development. However, the developed
tumors were small-cell osteosarcomas composed of small
round blue cells with osteoid formation. Small-cell osteo-
sarcoma is a rare subtype of osteosarcomas, accounting
for 1%–1.5% of all osteosarcomas (Nakajima et al., 1997).
Notably, small-cell osteosarcoma exhibits shared properties
with Ewing sarcoma (Righi et al., 2015). Moreover, EWSR1
rearrangement, which includes EWS-FLI1, has been identi-
fied in a subset of small-cell osteosarcomas (Dragoescu
et al., 2013; Hill et al., 2002; Noguera et al., 1990; Oshima
et al., 2004). The results of the present study demonstrate
that the EWS-FLI1 fusion gene could function as a driver
oncogene in a particular type of osteosarcoma and suggest
that our model could be a rodent model for EWS-FLI1-
dependent osteosarcomas.
The inhibition of differentiation has been considered to
play a role in many types of tumor development through
maintenance of the proliferating progenitor cell state.
Previous studies demonstrated that the knockdown of
EWS-FLI1 in Ewing sarcoma cell lines results in osteogenic,
adipogenic and chondrogenic differentiation (Tirode et al.,
2007). Similarly, in the present study, we found thatable by Dox exposure in qRT-PCR analyses. Data are presented as
f Dox OFF was set to 1.
ocompromised mice only in the presence of Dox (after 3–7 weeks of
all round blue cells that resembled small-cell osteosarcomas. HA
Scale bars, 200 mm (left) and 50 mm (right).
rs
EWS-FLI1-induced osteosarcomas exhibit robust osteo-
genic differentiation after the withdrawal of EWS-FLI1
expression, indicating that EWS-FLI1 expression inhibits
osteogenic differentiation. Molecular mechanisms by
which EWS-FLI1 expression blocks osteogenic differentia-
tion have been proposed in previous studies. It was re-
ported that EWS-FLI1 inhibits osteogenic differentiation
in murine multipotent mesenchymal cells by binding to
Runx2, an osteogenic transcription factor, and inhibiting
its function (Li et al., 2010). Similarly, EWSR1 was shown
to interact with SOX9, which is involved in chondrogenic
differentiation in zebrafish (Merkes et al., 2015). However,
we failed to detect a physical interaction between EWS-FLI1
and Runx2 or Sox9 in our osteosarcoma cells by immuno-
precipitation (data not shown), suggesting that another
mechanism may exist for the defective differentiation.
Notably, Riggi et al. (2014) demonstrated that EWS-FLI1
expression causes the displacement of endogenous ETS
transcription factors and p300 at the canonical ETS motifs
in Ewing sarcoma cells. We found that EWS-FLI1 binds to
the genome through the ETSmotif in EWS-FLI1-dependent
osteosarcoma cells. Given that the ETS family of transcrip-
tion factors plays an important role in osteogenic differen-
tiation as well as adipogenic and chondrogenic differentia-
tion (Birsoy et al., 2011; Iwamoto et al., 2007; Raouf and
Seth, 2000), the aberrantly occupied ETS motifs by EWS-
FLI1 might inhibit ETS family-mediated differentiation,
resulting in maintenance of the proliferating progenitor
state.
The majority of Ewing sarcomas arise in adolescence.
Considering the young age at onset, it is suggested that
Ewing sarcoma harbors few genetic abnormalities besides
the EWS-FLI1 fusion gene. Indeed, recent genome-wide
sequencing analyses revealed a paucity of somatic abnor-
malities (Crompton et al., 2014; Tirode et al., 2014). How-
ever, consistent with a number of previous studies, we
failed to induce sarcomas by the sole expression of EWS-
FLI1 in a variety of cell types in vivo, providing additional
evidence that EWS-FLI1 expression is not sufficient for sar-
coma development. Thus, we established iPSCs from EWS-
FLI1-induced osteosarcoma cells, thereby harboring the
same genetic abnormalities as the parental osteosarcoma
cells. Interestingly, upon the induction of osteogenic differ-
entiation, EWS-FLI1 expression turned sarcoma iPSC-
derived osteogenic cells into sarcoma cells, whereas the
expression was not sufficient for the transformation of
those from control ESCs/iPSCs.
It is noteworthy that sarcoma iPSCs showed an impair-
ment of terminal osteogenic differentiation ability irrespec-
tive of EWS-FLI1 expression. Notably, we found that
osteogenic lineage cells derived from sarcoma iPSCs exhibit
higher proliferating activity compared with cells derived
from control ESCs/iPSCs. Taken together, it is conceivableStemthat the additive effect by both EWS-FLI1 expression and
thedefective differentiationpropertiesof sarcoma iPSCspro-
motes sarcoma development by suppressing terminal differ-
entiationandmaintaining theproliferatingprogenitor state.
The causative aberration of the impaired differentiation
properties of sarcoma iPSCs remains unclear. Recently,
Lee et al. (2015) established iPSCs from patients with Li-
Fraumeni syndrome and demonstrated that mutant p53
causes defective osteoblastic differentiation. However, we
failed to detect the Trp53mutation in our sarcoma-derived
iPSCs (Table S2), implying an alternative mechanism
impairs osteogenic differentiation. Intriguingly, we ob-
served that sarcoma iPSC teratomas sometimes exhibited
impaired terminal differentiation of other lineages, which
is also consistent with the fact that they lack the potential
to make chimeric mice (Figure S5G). It is likely that a sum-
mation of extensive genetic abnormalities and epigenetic
alterations is associated with the impaired differentiation
of sarcoma iPSCs into multiple lineages. Further analysis
is needed to determine the aberrations required for the sar-
coma development associated with EWS-FLI1 expression.
The fact that the in vitro inductionof osteogenic differen-
tiation leads to sarcoma development from sarcoma iPSCs
in concert with EWS-FLI1 expression indicates that these
sarcomas arise from osteogenic progenitor cells. However,
it is important to note that the withdrawal of EWS-FLI1 in
osteosarcoma cells resulted in increased expression of mul-
tiple genes involved in chondrogenic andadipogenic differ-
entiation in addition to osteogenic differentiation-related
genes. Together with previous findings on Ewing sarcoma,
multipotent progenitors that have partial commitment to
the osteogenic lineage in the bone marrow could be a cell
of origin for EWS-FLI1-induced osteosarcomas. This notion
is also supported by the fact that a subset of small-cell oste-
osarcomas exhibits both chondrogenic and osteogenic dif-
ferentiation (Dragoescu et al., 2013; Nakajima et al., 1997).
In summary, we established an EWS-FLI1-dependent
small-cell osteosarcoma model by introducing EWS-FLI1
in mouse bone marrow stromal cells. We revealed that the
impaired differentiation associated with both EWS-FLI1
expression and sarcoma-associated genetic abnormalities
plays a critical role in the development and maintenance
of EWS-FLI1-induced osteosarcomas. We propose that tar-
geting impaired terminal differentiation could be a possible
therapeutic strategy for EWS-FLI1-induced sarcomas.EXPERIMENTAL PROCEDURES
In Vivo Experiment
Rosa-M2rtTA/Rosa:tetO-EWS-FLI1 and Rosa-M2rtTA/Col1a1::tetO-
EWS-FLI1 chimeric mice were generated with KH2 (Beard et al.,
2006). Rosa-M2rtTA/Rosa::tetO-EWS-FLI1 mice and immunocom-
promised mice inoculated with sarcoma cells were treated withCell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authors 603
Dox-containing water at 2 mg/ml with 10 mg/ml sucrose. Rosa-
M2rtTA/Col1a1::tetO-EWS-FLI1micewere treatedwith lowerconcen-
trations of Dox (100 mg/ml to 2mg/ml) because of early lethality. For
the xenograft assay, a total of 33 106 EWS-FLI1-dependent immor-
talized cells, EWS-FLI1-dependent sarcoma cells, or ESCs/iPSCs
were transplanted to immunocompromised mice. All animal exper-
iments were approved by the CiRA Animal Experiment Committee,
and the care of the animals was in accordance with institutional
guidelines.
iPSC Induction and Maintenance
iPSC induction was performed by utilizing retroviral vectors
(pMX-hOCT3/4, pMX-hSOX2, pMX-hKLF4, and pMX-hc-MYC;
Addgene). Reprogramming factor-inducing single-cell-derived sar-
coma cells were cultured in ESCmedia supplemented with human
recombinant leukemia inhibitory factor (LIF; Wako), 2-mercaptoe-
thanol (Invitrogen), and 50 mg/ml L-ascorbic acid (Sigma), and the
established iPSCs were maintained with ESC media supplemented
with LIF, 1 mM PD0325901 (Stemgent), and 3 mM CHIR99021
(Stemgent).
In Vitro Differentiation of ESC/iPSCs to Osteogenic
Lineage
We employed the in vitro osteogenic differentiation protocol as
described by Kim et al. (2010) with slight modifications. Briefly,
5,000 ESCs or iPSCs were cultured in a 96-well plate (Nunclon
Sphere, Thermo Scientific) with ES differentiation media (Iscove’s
modified Dulbecco’s medium, 15% FBS, penicillin/streptomycin,
L-glutamine, L-ascorbic acid, transferrin, thioglycerol) for 2 days.
On day 2, retinoic acid was added (final concentration, 106 M).
On day 5, embryoid bodies were collected, transferred to a 6-well
tissue culture dish, and cultured in osteogenic differentiation
media (a minimal essential medium, 10% FBS, penicillin/strepto-
mycin, L-glutamine, 2 nM triiodothyronine, ITS). The media
were changed every other day. On day 17, RNA was extracted,
and osteogenic gene expression of the induced osteogenic cells
was confirmed by real-time quantitative RT-PCR. Alizarin red stain-
ing was performed on day 28.
Array Comparative Genomic Hybridization
Genomic DNA was extracted with PureLink Genomic DNA Mini
Kit (Invitrogen). Array comparative genomic hybridization anal-
ysis was performed with SurePrint G3 Mouse Genome CGH
MicroarrayKit (Agilent) and analyzedwithAgilentGenomicWork-
bench 7.0.
Microarray Analysis
200ngof totalRNApreparedwithanRNeasyMiniKitwas subjected
to cDNA synthesis with a WT Expression Kit (Ambion), and the
resultant cDNA was fragmented and hybridized to a Mouse Gene
1.0 ST Array (Affymetrix). The data obtained were analyzed using
GeneSpring GX software (version 13.0, Agilent Technologies).
ChIP-Seq Analysis
ChIP (formaldehyde-assisted isolation of regulatory elements) was
performed as described previously (Arioka et al., 2012). Anti-HA604 Stem Cell Reports j Vol. 6 j 592–606 j April 12, 2016 j ª2016 The Authoantibody (Nacalai, HA124, 06340-54) was used for the ChIP-seq
analysis. Sequencing libraries were generated using a TruSeq
ChIP Sample Prep Kit (Illumina). The libraries were sequenced to
generate single-end 100-bp reads using Illumina MiSeq. We used
theMACS (Zhang et al., 2008) version 1.4.2 peak finding algorithm
to identify regions of ChIP-seq enrichment over backgroundwith a
p value 1 3 103. Ngs.plot was used to analyze and visualize the
mapped reads (Shen et al., 2014). Themotif analysis was performed
using HOMER software (Heinz et al., 2010).
Exome Analysis
Genomic DNA of SCOS#2-A1, sarcoma iPSC#2-A1, and sarcoma-
iPSC#2-A1-derived secondary sarcoma was extracted with a
PureLink Genomic DNA Mini Kit (Invitrogen). Whole-exome
capture was done with SureSelect XT (Agilent Technologies). The
exome libraries were then sequenced on a HiSeq2500 (Illumina).
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